Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...

As non-animal models move mainstream, the focus is shifting toward reproducibility and data integrity. By using specialized ...

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Advances in Cell-based Screening 2026, taking place at ...

-Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified ...

Researchers developed a DNA barcoding assay to measure nanoparticle cargo escape in living organisms, enabling a new class of lipid nanoparticles for more efficient gene editing.

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression because of shared inflammatory pathways.

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has announced the publication 1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial ...

Nina Bauer of FUJIFILM Cellular Dynamics shares insight on addressing challenges and supporting developers heading towards commercialization.

In this GEN Learning Lab, our expert panelists Linda Orzolek, MS, MB, Xuhuai Ji, MD, PhD, and Christina Chang, PhD, will discuss the current landscape of imaging- and next-generation sequencing-based ...

ViruSure, an Asahi Kasei company and global leader in pathogen safety testing for biopharmaceuticals, today announced the launch of the world's first GMP-validated adventitious viral agent (AVA) ...